Bouwhuis Saskia A, Davis Mark D P, el-Azhary Rokea A, McEvoy Marian T, Gibson Lawrence E, Knudsen John M, Kist Joseph M, Pittelkow Mark R
Departments of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Am Acad Dermatol. 2005 Jun;52(6):991-6. doi: 10.1016/j.jaad.2005.02.055.
Bexarotene is a retinoid drug that is approved for the treatment of cutaneous T-cell lymphoma. We report 6 cases in which the initiation of bexarotene therapy for cutaneous T-cell lymphoma was temporally associated with the progression of internal disease despite improvement in cutaneous signs and symptoms. It is possible that bexarotene contributed to this progression. Although bexarotene therapy may alleviate symptoms and signs of cutaneous T-cell lymphoma, careful surveillance of lymph nodes and solid organs during treatment is advised.
贝沙罗汀是一种已被批准用于治疗皮肤T细胞淋巴瘤的类视黄醇药物。我们报告了6例病例，其中尽管皮肤症状和体征有所改善，但在开始使用贝沙罗汀治疗皮肤T细胞淋巴瘤时，内部疾病却出现了进展。贝沙罗汀有可能导致了这种进展。虽然贝沙罗汀治疗可能会缓解皮肤T细胞淋巴瘤的症状和体征，但建议在治疗期间对淋巴结和实体器官进行仔细监测。
